Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS61DB)

Drug Name

KNI-227 Drug Info

Synonyms

Kynostatin 227; Kni-227; Kynostatin-227; 147384-69-8; CHEMBL231622; KYNOSTATIN; Qoa-Mta-Apns-Thz-NH-tBu; AC1L22EK; AC1Q5L2G; BDBM719; SCHEMBL2772022; DTXSID30163692; N-(1,1-Dimethylethyl)-3-[2-hydroxy-3-[[2-[[(5-isoquinolinyloxy)acetyl]amino]-3-methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl]-5,5-dimethyl]-4-thiazolidinecarboxamide,[4R-[3[2S*,3S*(R*)],4R*]]; (4R)-N-tert-Butyl-3-[(2S,3S)-2-hydroxy-3-[S-methyl-N-(5-isoquinolinyloxyacetyl)-L-cysteinylamino]-4-phenylbutyryl]-5,5-dimethylthiazolidine-4alpha-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 65012
CAS Number: CAS 147384-69-8
TTD Drug ID: DMS61DB

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Plasmodium Plasmepsin 2 (Malaria PLA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US9353089, 135	DMWG98Z	N. A.	N. A.	Patented	[2]
US9353089, 330	DMK02LS	N. A.	N. A.	Patented	[2]
US9353089, 327	DMB4MJ0	N. A.	N. A.	Patented	[2]
Pepstatin	DM9S1EA	Malaria	1F40-1F45	Terminated	[3]
Leupeptin	DMU075F	Malaria	1F40-1F45	Investigative	[3]
E-64	DMMOPAK	Discovery agent	N.A.	Investigative	[4]
KNI-10006	DMMISH6	Discovery agent	N.A.	Investigative	[5]
PS-777621	DM3F7SD	Discovery agent	N.A.	Investigative	[6]
PS-662477	DMT4YFR	Discovery agent	N.A.	Investigative	[7]
KNI-10740	DMPWY6H	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Plasmodium Plasmepsin 2 (Malaria PLA2)	TTXMNHO	PLM2_PLAFA	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52.
2	Compositions and methods for the treatment of malaria. US9353089.
3	Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
4	Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrob Agents Chemother. 1998 Sep;42(9):2254-8.
5	Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9.
6	High antiplasmodial activity of novel plasmepsins I and II inhibitors. J Med Chem. 2006 Dec 14;49(25):7440-9.
7	Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library. Bioorg Med Chem Lett. 1998 Sep 8;8(17):2315-20.